Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma

Ryan Lynch, David Russler-Germain, Joseph Schroers-Martin, Alison Moskowitz, Reid Merryman, Azra Borogovac, Hongyan Du, Heather Rasmussen, Ranjana Advani, Ash Alizadeh, Philippe Armand, Nancy Bartlett, Alex Herrera, Matthew Mei, Sarah Rutherford, David Kurtz, Ted Gooley, Jenna Voutsinas, Ajay Gopal

Blood (2025) 146 (Supplement 1): 5408.

https://doi.org/10.1182/blood-2025-5408

Published: 2025

Journal Articles

Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis

Ryan Lynch, Christina Poh, Mazyar Shadman, Brian Till, Mengyang Di, Chaitra Ujjani, Vikram Raghunathan, Stephen Smith, David Maloney, Daria Gausman, Heather Rasmussen, David Russler-Germain, Todd Fehniger, David Kurtz, Ash Alizadeh, Jenna Voutsinas, Ajay Gopal

Blood (2025) 146 (Supplement 1): 3591.

https://doi.org/10.1182/blood-2025-3591

Published: 2025

Journal Articles

FLP-R: A clinical prediction model for follicular lymphoma Prognosis in the Relapsed/refractory setting

Blood (2025) 146 (Supplement 1): 5354.

https://doi.org/10.1182/blood-2025-5354

Published: 2025

Journal Articles

Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy

Blood (2025) 146 (Supplement 1): 471.

https://doi.org/10.1182/blood-2025-471

Published: 2025

Journal Articles

Non-invasive classification & molecular subtyping of mature lymphoid neoplasms by cell-free DNA profiling

Blood (2025) 146 (Supplement 1): 5330.

https://doi.org/10.1182/blood-2025-5330

Published: 2025

Journal Articles

Favorable preliminary safety and efficacy of mosunetuzumab plus ICE or DHAX salvage chemotherapy in relapsed/refractory large B-cell lymphoma

David Russler-Germain, Hunter Cochran, Fei Wan, Amalia Dubois, Chaz Moreno, Francesca Loyet, Dilan Patel, Brad Kahl, Todd Fehniger, Amanda Cashen, Armin Ghobadi, Neha Mehta-Shah, Nancy Bartlett

Blood (2025) 146 (Supplement 1): 5508.

https://doi.org/10.1182/blood-2025-5508

Published: 2025

Journal Articles

primary analysis of Phase ib trial of duvelisib for cytokine release syndrome prophylaxis in patients undergoing chimeric antigen receptor T cell therapy for non-hodgkins lymphoma

Michael Slade, Michael Rettig, Parmeshwar Amatya, Zachary Crees, Brad Kahl, Neha Mehta-Shah, Dilan Patel, David Russler-Germain, Nancy Bartlett, Amanda Cashen, Iskra Pusic, Geoffrey Uy, John DiPersio, Armin Ghobadi

Blood (2025) 146 (Supplement 1): 929.

https://doi.org/10.1182/blood-2025-929

Published: 2025

Journal Articles

Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 784.

https://doi.org/10.1182/blood-2025-784

Published: 2025

Journal Articles

DNMT3A -Dependent DNA Methylation May Act As a Tumor Suppressor-Not a Tumor Promoter-during AML Progression

David Spencer, MDPhD, David Russler-Germain, Nichole M Helton, B.S., Tamara L Lamprecht, B.S., Marwan Shinawi, MD, Peter Westervelt, MD PhD, Jacqueline E. Payton, MD PhD, Robert S. Fulton, PhD, Richard K Wilson, PhD, Matthew J. Walter, MD, Daniel C. Link, MD, John F. DiPersio, MD, PhD, Timothy J. Ley, MD

Blood (2016) 128 (22): 1050.

https://doi.org/10.1182/blood.V128.22.1050.1050

Published: 2016

Journal Articles

Whole-Genome Bisulfite Sequencing of Primary AML Cells with the DNMT3A R882H Mutation Identifies Regions of Focal Hypomethylation That Are Associated with Open Chromatin

David H. Spencer, MDPhD, Bilal Al-Khalil, David Russler-Germain, Tamara Lamprecht, Nicole Havey, Robert S. Fulton, Michelle O'Laughlin, BS, Catrina Fronick, Richard K. Wilson, PhD, Timothy J. Ley, MD

Blood (2014) 124 (21): 608.

https://doi.org/10.1182/blood.V124.21.608.608

Published: 2014

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma

Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis

FLP-R: A clinical prediction model for follicular lymphoma Prognosis in the Relapsed/refractory setting

Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy

Non-invasive classification & molecular subtyping of mature lymphoid neoplasms by cell-free DNA profiling

Favorable preliminary safety and efficacy of mosunetuzumab plus ICE or DHAX salvage chemotherapy in relapsed/refractory large B-cell lymphoma

primary analysis of Phase ib trial of duvelisib for cytokine release syndrome prophylaxis in patients undergoing chimeric antigen receptor T cell therapy for non-hodgkins lymphoma

Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma

DNMT3A -Dependent DNA Methylation May Act As a Tumor Suppressor-Not a Tumor Promoter-during AML Progression

Whole-Genome Bisulfite Sequencing of Primary AML Cells with the DNMT3A R882H Mutation Identifies Regions of Focal Hypomethylation That Are Associated with Open Chromatin

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only